Kamada (NASDAQ:KMDA) Reaches New 12-Month High – Still a Buy?

Kamada Ltd. (NASDAQ:KMDA) shares hit a new 52-week high on Tuesday . The company traded as high as $9.27 and last traded at $9.1760, with a volume of 53245 shares. The stock had previously closed at $8.88.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on KMDA shares. HC Wainwright boosted their target price on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Benchmark reissued a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kamada Stock Up 3.8%

The stock has a fifty day simple moving average of $7.93 and a 200 day simple moving average of $7.29. The firm has a market capitalization of $529.90 million, a P/E ratio of 25.55, a PEG ratio of 0.75 and a beta of 0.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Essex Investment Management Co. LLC increased its holdings in shares of Kamada by 22.4% in the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after purchasing an additional 72,602 shares during the last quarter. Y.D. More Investments Ltd grew its holdings in Kamada by 7.3% during the 4th quarter. Y.D. More Investments Ltd now owns 289,382 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 19,717 shares in the last quarter. Acadian Asset Management LLC increased its stake in Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after acquiring an additional 7,925 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Kamada by 1.2% during the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock worth $1,779,000 after acquiring an additional 2,943 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Kamada by 25.9% during the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock valued at $1,390,000 after acquiring an additional 40,514 shares during the last quarter. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.